Analyst Ratings February 3, 2026

UBS Sticks With Buy on Peloton, Sees Large Upside if Churn Holds Flat

Analyst note maintains $11 target as Peloton reports improved churn and readies for cost cuts ahead of fiscal Q2 2026 earnings

By Avery Klein PTON
UBS Sticks With Buy on Peloton, Sees Large Upside if Churn Holds Flat
PTON

UBS has reiterated a Buy rating on Peloton Interactive (PTON) with an $11.00 price target, implying roughly 90% upside from the current $5.80 share price. The brokerage highlights better-than-expected Q1 churn improvement and notes that Peloton is guiding to flat year-over-year churn for the full fiscal year, while flagging a near-term Q2 churn increase before sequential improvement. The stock appears to price in weaker churn and sharper subscriber additions declines than UBS's scenarios would suggest. Other developments include an 11% workforce reduction, a trimmed price target from BofA, a Market Perform view from Citizens, a health study finding on menopause symptom improvement, and board re-elections at the annual meeting.

Key Points

  • UBS maintains a Buy rating on Peloton with an $11.00 price target, implying roughly 90% upside from a $5.80 share price and above the $9.40 analyst consensus average.
  • Peloton reported a 20 basis point year-over-year improvement in Q1 churn and is guiding to roughly flat churn for the full fiscal year, with an expected Q2 uptick of about 80 basis points followed by improvements in Q3 and Q4.
  • Recent company moves include an 11% workforce reduction focused primarily on engineering roles, and analysts hold mixed views: BofA lowered its target to $9 but kept Buy, while Citizens reiterated a Market Perform rating.

UBS has reiterated a Buy rating on Peloton Interactive (NASDAQ:PTON) and kept its price target at $11.00, according to a recent analyst note. That target represents about a 90% increase from the companys current share price of $5.80 and sits above the broader analyst consensus average price target of $9.40. Data from InvestingPro indicates Peloton is trading below its assessed Fair Value, implying room for upside if operational metrics stabilize or improve.

The UBS note emphasized churn dynamics as central to their outlook. Peloton reported a 20 basis point year-over-year improvement in Q1 churn, a result UBS says meaningfully exceeded market expectations. Managements full-year guidance calls for churn to be roughly flat year-over-year.

UBS detailed the cadence embedded in that guidance: a projected Q2 churn increase of about 80 basis points on a year-over-year basis, followed by sequential improvements of around 20 basis points in both Q3 and Q4 versus the prior year. The firm believes the current share price appears to reflect a scenario worse than flat churn for the year.

In UBSs scenario work, if churn holds flat for the fiscal year, the market-implied valuation is consistent with gross subscriber additions declining by more than 20% for the year, after an estimated 14.6% decline in fiscal 2025. UBS also noted that Peloton could see gross additions drop by more than 20% and still align with expectations for an 8% to 9% decline in total subscribers, should churn remain flat.

On the profitability front, Peloton posted a loss of $0.26 per share over the last twelve months. InvestingPro data indicates analysts expect Peloton to achieve positive earnings this fiscal year, with a consensus EPS forecast of $0.15. The companys liquidity position remains solid on a short-term basis, with a current ratio of 1.9, which UBS views as supportive as management implements its turnaround plan. Investors may also access a comprehensive Pro Research Report on Peloton among the InvestingPro coverage universe.


Corporate and operational developments have continued to unfold. Peloton announced an 11% reduction in its workforce as part of a cost-cutting initiative led by CEO Peter Stern. The layoffs mainly affect engineering roles tied to technology and enterprise projects.

On the analyst front, BofA Securities trimmed its price target on Peloton from $11 to $9 while maintaining a Buy rating. That adjustment was issued in advance of Pelotons fiscal second-quarter 2026 earnings report, which is scheduled for February 5. Separately, a Citizens analyst reiterated a Market Perform rating, noting cautious optimism that expense management could produce favorable EBITDA outcomes.

Other items of note reported by the company include a study conducted with Respin Health, which found that 84% of women experienced improvements in menopause symptoms after completing a 60-day Peloton fitness program. At Pelotons recent annual meeting, shareholders re-elected directors Karen Boone, Chris Bruzzo, and Tara Comonte and approved the companys auditor, reflecting continuity in board composition and governance oversight.

Taken together, UBSs reiteration of a Buy rating centers on a view that the stock currently discounts a downside churn scenario that may not materialize, while the companys liquidity and cost actions leave it positioned to execute a recovery plan. Market participants will be watching upcoming churn prints and the February earnings report for confirmation of the guidance cadence and subscriber trends.

Risks

  • Churn could worsen above the levels embedded in managements guidance, which would negatively affect subscriber metrics and revenue - impacting the consumer fitness and subscription revenue sectors.
  • Continued declines in gross subscriber additions, if larger than UBSs scenarios, could pressure the stock further and hurt expectations for the company's turnaround - relevant to investors in leisure hardware and recurring subscription businesses.
  • Execution risk around cost reductions and product investments exists as Peloton trims staff, particularly in engineering and enterprise projects, which could affect innovation and enterprise growth initiatives in the technology and fitness sectors.

More from Analyst Ratings

Freedom Capital Upholds Sell on ExxonMobil, Keeps $123 Target Despite Strong Ops Feb 3, 2026 Freedom Capital Keeps Buy on Flexsteel After Strong Q2; $54 Price Target Intact Feb 3, 2026 UBS Lifts ExxonMobil Price Target to $171 After Q4 Results Amid Operational Headwinds Feb 3, 2026 UBS Stays Bullish on Tenet as Conifer Ownership and Contract Terms Shift Feb 3, 2026 UBS Sticks With Neutral on Crocs as Market Sentiment Skews Bearish Feb 3, 2026